Research Topics
Genomes and GenesSpecies | Aldo M RoccaroSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemiaAldo M Roccaro
Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
Blood 111:4752-63. 2008..Theses studies enhance our understanding of the biologic role of the proteasome pathway in WM, and provide the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM...
Bortezomib in the treatment of cancerAldo M Roccaro
Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
Recent Patents Anticancer Drug Discov 1:397-403. 2006..This reviews focuses on the proteasome inhibition exerted by bortezomib, the first proteasome inhibitor to have shown anti-cancer activity in both solid and haematologic malignancies...
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemiaAldo M Roccaro
Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
Clin Cancer Res 14:1849-58. 2008..Whether resveratrol could inhibit proliferation or induce cytotoxicity in Waldenström's macroglobulinemia (WM) was investigated...- microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaAldo M Roccaro
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Blood 113:4391-402. 2009..These data indicate that microRNAs play a pivotal role in the biology of WM; represent important prognostic marker; and provide the basis for the development of new microRNA-based targeted therapies in WM... - Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biologyAntonio Sacco
Dana Farber Cancer Institute, Medical Oncology, Harvard Medical School, Boston, MA, USA
J Hematol Oncol 3:38. 2010..These findings provide a better understanding of the underlying molecular changes that lead to the initiation and progression of this disease... - Anti-angiogenic therapies in the treatment of Waldenstrom's MacroglobulinemiaA Sacco
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 02115 Boston, MA, USA
Curr Cancer Drug Targets 11:1025-9. 2011.... - Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's MacroglobulinemiaAntonio Sacco
Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 17:1753-64. 2011..We therefore evaluated carfilzomib, a potent selective, irreversible inhibitor of the CT-L activity of the i20S and c20S in WM cells... - MicroRNAs 15a and 16 regulate tumor proliferation in multiple myelomaAldo M Roccaro
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Blood 113:6669-80. 2009..These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM... - microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemiaAldo M Roccaro
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Blood 116:1506-14. 2010..These findings confirm that histone-modifying genes and HDAC activity are deregulated in WM cells, partially driven by the aberrant expression of miRNA-206 and -9* in the tumor clone... - FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 65:7478-84. 2005..These results suggest that FTY720 overcomes drug resistance in multiple myeloma cells and provide the rationale for its clinical evaluation to improve patient outcome in multiple myeloma... - CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyAbdel Kareem Azab
Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Blood 113:4341-51. 2009..These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy... - Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaXavier Leleu
Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Blood 113:626-34. 2009..Finally, we demonstrate that ER stress inducer synergizes with other agents used in the treatment of WM. These preclinical studies provide a framework for further evaluation of ER stress inducing agents as therapeutic agents in WM... - Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemiaAldo M Roccaro
Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Blood 115:4051-60. 2010..These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid antitumor therapy in WM... - Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosisKenji Ishitsuka
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:1794-800. 2005..Taken together, our results provide the preclinical rationale for clinical protocols of HNK to improve patient outcome in MM... - FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferationAbdel Kareem Azab
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 17:4389-99. 2011..Cell cycle was performed by PI staining of cells and flow cytometry. The combinatory effect of dovitinib with other drugs was analyzed using Calcusyn software. The effect of dovitinib was tested in vivo... - Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathwayKenji Ishitsuka
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Oncogene 24:5888-96. 2005.... - Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemiaHai T Ngo
Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 15:6035-41. 2009..We sought to determine whether the protein tyrosine kinase Src regulates adhesion, migration, and survival in Waldenstrom macroglobulinemia... - P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironmentAbdel Kareem Azab
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 119:1468-78. 2012..These data highlight the critical contribution of PSGL-1 to the regulation of growth, dissemination, and drug resistance in MM in the context of the BM microenvironment... - Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemiaFeda Azab
Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 18:91-104. 2012..In this study, we characterized the role of Eph-B2 receptor in the interaction of Waldenstrom's macroglobulinemia (WM) cells with the bone marrow microenvironment... - Role of proteasome inhibition in Waldenström's macroglobulinemiaAldo M Roccaro
Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
Clin Lymphoma Myeloma 9:94-6. 2009..Among them the role of proteasome inhibitors has been widely dissected providing the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM... - Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu
Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
Blood 111:5068-77. 2008..Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-kappaB pathway... - Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresAbdel Kareem Azab
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 119:5782-94. 2012..Further studies to manipulate hypoxia to regulate tumor dissemination as a therapeutic strategy are warranted... - Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemiaAldo M Roccaro
Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
Blood 115:559-69. 2010..These studies therefore show that dual targeting of the PI3K/mTOR pathway is a better modality of targeted therapy for tumors that harbor activation of the PI3K/mTOR signaling cascade, such as WM... - Targeting the bone marrow in Waldenstrom macroglobulinemiaIrene M Ghobrial
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Lymphoma Myeloma Leuk 11:S65-9. 2011..These include chemokines, adhesion molecules, Src/PI3K/Akt/mTOR signaling, NF-kB activation, and micro-RNA regulation in WM. Targeting these pathways in clinical trials could lead to significant responses in this rare disease... - Defining the role of TORC1/2 in multiple myelomaPatricia Maiso
Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 118:6860-70. 2011..Dual TORC1/2 inhibition showed better inhibition of adhesion to BM microenvironmental cells and inhibition of homing in vivo. These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM... - Waldenstrom macroglobulinemiaXavier Leleu
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Cancer Lett 270:95-107. 2008..This report provides an update of the current preclinical studies and clinical efforts for the development of novel agents in the treatment of WM... - Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Leuk Lymphoma 50:694-702. 2009.... - Key role of microRNAs in Waldenström's macroglobulinemia pathogenesisAntonio Sacco
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Clin Lymphoma Myeloma Leuk 11:109-11. 2011..It has been recently demonstrated that microRNAs may be responsible for modulating histone acetylation in WM cells, thus providing the preclinical evidences for using microRNA-based therapeutic strategies in this disease... - The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemiaAnne Sophie Moreau
Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
Br J Haematol 142:775-85. 2008..Our studies therefore support our earlier observation of statin-mediated anti-WM activity and provide the framework for future clinical trials testing simvastatin in WM... - LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomasYong Zhang
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 120:1678-86. 2012..The results of the present study highlight the therapeutic potential of anti-miR-155-mediated inhibition of miR-155 in the treatment of WM... - Update on therapeutic options in Waldenström macroglobulinemiaXavier Leleu
Kirsch Laboratory for Waldenström macroglobulinemia, Department of Medical Oncology, Dana Farber Cancer Institute DFCI and Harvard Medical School, Boston, MA, USA
Eur J Haematol 82:1-12. 2009..This report provides an update of the current preclinical studies and clinical efforts for the development of novel agents in the treatment of WM... - Epigenetics in Waldenström's macroglobulinemiaAntonio Sacco
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Epigenomics 2:691-6. 2010..In this study it has been demonstrated that WM patients present with a specific miRNA signature. Among deregulated miRNAs, miR-155 and miR-9* play a pivotal role in the pathogenesis of this disease... - Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemiaAldo M Roccaro
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 18:6609-22. 2012..We therefore sought to dissect the mechanisms of everolimus-dependent modulation of Waldenstrom macroglobulinemia cell survival... - RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myelomaAbdel Kareem Azab
Medical Oncology, Dana Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, 44 Binney Street, Boston, MA, USA
Blood 114:619-29. 2009..In conclusion, we characterized the role of RhoA and Rac1 GTPases in SDF1-induced adhesion, chemotaxis, and homing of MM cells to the BM, providing the framework for targeting RhoA and Rac1 GTPases as novel MM therapy... - Targeted therapies in Waldenström macroglobulinemiaNicholas Burwick
Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
Curr Opin Investig Drugs 9:631-7. 2008..In this review, the novel therapeutics that target these pathways are discussed... - Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu
Bing Center for Waldenstrom s Macroglobulinemia and Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
Br J Haematol 145:59-63. 2009..These data depict for the first time a heterogeneous expression pattern of the genes involved in late differentiation process of plasma cells in patients with WM and propose a role of XBP1-ERN1alpha in WM pathogenesis... - Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaSimona Blotta
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 120:5002-13. 2012..Altogether, our data demonstrate activation of both canonical and noncanonical Hh pathway in MM, thus providing the rationale for testing Hh inhibitors in clinical trials to improve MM patient outcome... - Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemiaXavier Leleu
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School Boston, MA 02115, USA
Leuk Lymphoma 49:1104-7. 2008..This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients... - Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
Biologics 2:419-31. 2008.... - New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemiaGhayas C Issa
Medical Oncology, Pharmacy Department, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Hematol 18:260-5. 2011..There have been recent significant advances in understanding the underlying pathogenesis of this disease, including genetic and epigenetic regulators of tumor progression... - SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
Blood 106:706-12. 2005..Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clinically relevant concentrations, targets Mcl-1, and can be synergistically combined with Dex... - Development of vasculature targeting strategies for the treatment of chronic inflammatory diseasesGirolamo Ranieri
National Cancer Institute, Department of Clinical and Experimental Oncology, Bari, Italy
Curr Drug Targets Inflamm Allergy 4:13-22. 2005.... - Clinical relevance of soluble HLA class I molecules in Waldenstrom MacroglobulinemiaAnne Sophie Moreau
Service des Maladies du Sang, CHRU, Lille, France
Eur J Haematol 80:503-9. 2008..Beta-2 microglobulin (b2m) is a major prognostic factor in WM and the heavy chain of HLA class I molecules, which are known to have immunosuppressive properties and have been implicated in the pathogeny of several malignancies... - Hematopoietic cancer and angiogenesisDomenico Ribatti
Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy
Stem Cells Dev 13:484-95. 2004....